ECSP21003171A - Dinucleótidos cíclicos como agonistas de sting - Google Patents

Dinucleótidos cíclicos como agonistas de sting

Info

Publication number
ECSP21003171A
ECSP21003171A ECSENADI20213171A ECDI202103171A ECSP21003171A EC SP21003171 A ECSP21003171 A EC SP21003171A EC SENADI20213171 A ECSENADI20213171 A EC SENADI20213171A EC DI202103171 A ECDI202103171 A EC DI202103171A EC SP21003171 A ECSP21003171 A EC SP21003171A
Authority
EC
Ecuador
Prior art keywords
sting agonists
cyclic dinucleotides
sting
compounds
dinucleotides
Prior art date
Application number
ECSENADI20213171A
Other languages
English (en)
Inventor
Leonid Beigelman
Wim Bert Griet Schepens
Santhosh Kumar Thatikonda
Guangyi Wang
Gilles Bignan
Johannes Wilhelmus J F Thuring
Peter J Connolly
Marcel Viellevoye
Mark Richter
Stuart Emanuel
James P Edwards
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of ECSP21003171A publication Critical patent/ECSP21003171A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

Se describen compuestos, composiciones y métodos para tratar enfermedades, síndromes o trastornos que se ven afectados por la modulación de STING. Tales compuestos se representan mediante la Fórmula (I): (VER ANEXO) En donde R1, R1’, X1, B1, R2, R2’, B2, X2, R3, Z-M-Y y Y1-M1-Z1 son como se definen en la presente descripción.
ECSENADI20213171A 2018-07-17 2021-01-15 Dinucleótidos cíclicos como agonistas de sting ECSP21003171A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862699001P 2018-07-17 2018-07-17

Publications (1)

Publication Number Publication Date
ECSP21003171A true ECSP21003171A (es) 2021-02-26

Family

ID=67999987

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20213171A ECSP21003171A (es) 2018-07-17 2021-01-15 Dinucleótidos cíclicos como agonistas de sting

Country Status (20)

Country Link
US (2) US11597746B2 (es)
EP (1) EP3823976A1 (es)
JP (1) JP2021531277A (es)
KR (1) KR20210033026A (es)
CN (1) CN112424212A (es)
AR (1) AR122240A1 (es)
AU (1) AU2019304230B2 (es)
BR (1) BR112021000693A2 (es)
CA (1) CA3106602A1 (es)
EA (1) EA202190298A1 (es)
EC (1) ECSP21003171A (es)
IL (1) IL280105A (es)
MA (1) MA53178A (es)
MX (1) MX2021000625A (es)
PE (1) PE20211636A1 (es)
PH (1) PH12020552172A1 (es)
SG (1) SG11202012624RA (es)
TW (1) TW202030199A (es)
UY (1) UY38304A (es)
WO (1) WO2020016782A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3724205B1 (en) * 2017-12-15 2022-06-22 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
TW202030199A (zh) * 2018-07-17 2020-08-16 美商健生生物科技公司 作為ｓｔｉｎｇ促效劑之環狀二核苷酸
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX363780B (es) * 2015-12-03 2019-04-03 Glaxosmithkline Ip Dev Ltd Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón.
CN109451740B (zh) * 2016-01-11 2022-09-02 先天肿瘤免疫公司 用于治疗与sting活性相关的病症诸如癌症的环状二核苷酸
US10723756B2 (en) * 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
HRP20221263T1 (hr) 2016-03-18 2023-03-03 Immune Sensor, Llc Ciklički di-nukleotidni spojevi i postupci uporabe
AU2017293781B2 (en) * 2016-07-06 2022-12-22 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2018045204A1 (en) 2016-08-31 2018-03-08 Ifm Therapeutics, Inc Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
JOP20170188A1 (ar) * 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
TW202030199A (zh) * 2018-07-17 2020-08-16 美商健生生物科技公司 作為ｓｔｉｎｇ促效劑之環狀二核苷酸

Also Published As

Publication number Publication date
WO2020016782A1 (en) 2020-01-23
AU2019304230A1 (en) 2021-01-14
PE20211636A1 (es) 2021-08-24
US20230287034A1 (en) 2023-09-14
KR20210033026A (ko) 2021-03-25
PH12020552172A1 (en) 2021-06-07
CN112424212A (zh) 2021-02-26
UY38304A (es) 2020-01-31
US11597746B2 (en) 2023-03-07
CA3106602A1 (en) 2020-01-23
IL280105A (en) 2021-03-01
US20210277046A1 (en) 2021-09-09
AU2019304230B2 (en) 2023-08-31
AR122240A1 (es) 2022-08-31
TW202030199A (zh) 2020-08-16
JP2021531277A (ja) 2021-11-18
EA202190298A1 (ru) 2021-04-16
SG11202012624RA (en) 2021-02-25
MA53178A (fr) 2021-05-26
MX2021000625A (es) 2021-03-25
BR112021000693A2 (pt) 2021-04-13
EP3823976A1 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
CO2019006622A2 (es) Derivados de pirazol como inhibidores de malt1
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
CO2021005987A2 (es) Compuestos de anillo fusionado
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
CO2019004137A2 (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
MX2021013193A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
EA201892147A1 (ru) Бициклические соединения
JOP20170188A1 (ar) ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
MX2020004538A (es) Moduladores de la vía de estrés integrada.
MX2020004534A (es) Moduladores de la vía integrada del estrés.
UY38476A (es) Inhibidores de arg1 y/o arg2
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
UY36949A (es) 2,4-dihidroxi-nicotinamidas como agonistas de apj
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
MX2020006290A (es) Dinucleotidos ciclicos como agonistas de sting.
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
EA201990400A1 (ru) Соединения и композиции и их применение
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
CL2020001107A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.